[go: up one dir, main page]

SE7810946L - Metod att behandla kronisk obstruktiv luftvegssjukdom - Google Patents

Metod att behandla kronisk obstruktiv luftvegssjukdom

Info

Publication number
SE7810946L
SE7810946L SE7810946A SE7810946A SE7810946L SE 7810946 L SE7810946 L SE 7810946L SE 7810946 A SE7810946 A SE 7810946A SE 7810946 A SE7810946 A SE 7810946A SE 7810946 L SE7810946 L SE 7810946L
Authority
SE
Sweden
Prior art keywords
chronic obstructive
treating chronic
obstructive air
air disease
disease
Prior art date
Application number
SE7810946A
Other languages
English (en)
Inventor
P G Kjellin
C G A Persson
Original Assignee
Draco Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20336144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE7810946(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SE7810946A priority Critical patent/SE7810946L/sv
Application filed by Draco Ab filed Critical Draco Ab
Priority to EP79850091A priority patent/EP0011609B2/en
Priority to EP81106977A priority patent/EP0045094B1/en
Priority to AT81106977T priority patent/ATE7495T1/de
Priority to AT79850091T priority patent/ATE2999T1/de
Priority to DE7979850091T priority patent/DE2965208D1/de
Priority to DE8181106977T priority patent/DE2967002D1/de
Priority to US06/082,402 priority patent/US4325956A/en
Priority to AU51872/79A priority patent/AU529805B2/en
Priority to IE1988/79A priority patent/IE49623B1/en
Priority to IE150785A priority patent/IE49624B1/en
Priority to JP13584479A priority patent/JPS5557517A/ja
Publication of SE7810946L publication Critical patent/SE7810946L/sv
Priority to US06/273,213 priority patent/US4804664A/en
Priority to SG32486A priority patent/SG32486G/en
Priority to HK714/86A priority patent/HK71486A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE7810946A 1978-10-20 1978-10-20 Metod att behandla kronisk obstruktiv luftvegssjukdom SE7810946L (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE7810946A SE7810946L (sv) 1978-10-20 1978-10-20 Metod att behandla kronisk obstruktiv luftvegssjukdom
EP79850091A EP0011609B2 (en) 1978-10-20 1979-09-28 Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease
EP81106977A EP0045094B1 (en) 1978-10-20 1979-09-28 Intermediates for the preparation of therapeutically active xanthine derivatives
AT81106977T ATE7495T1 (de) 1978-10-20 1979-09-28 Zwischenprodukte fuer die herstellung therapeutisch wirksamer xanthinderivate.
AT79850091T ATE2999T1 (de) 1978-10-20 1979-09-28 Xanthinderivate und pharmazeutische zusammensetzung zur verwendung fuer die behandlung chronischer verstopfungen der atemwege und von herzkrankheiten.
DE7979850091T DE2965208D1 (en) 1978-10-20 1979-09-28 Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease
DE8181106977T DE2967002D1 (en) 1978-10-20 1979-09-28 Intermediates for the preparation of therapeutically active xanthine derivatives
US06/082,402 US4325956A (en) 1978-10-20 1979-10-05 Method and pharmaceutical preparation for treating chronic obstructive airway disease and cardiac disease, and intermediates for the preparation of therapeutically active xanthine derivatives
AU51872/79A AU529805B2 (en) 1978-10-20 1979-10-17 Xanthine compositions
IE1988/79A IE49623B1 (en) 1978-10-20 1979-10-18 Xanthine derivatives,pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease
IE150785A IE49624B1 (en) 1978-10-20 1979-10-18 Intermediates for the preparation of xanthine derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease
JP13584479A JPS5557517A (en) 1978-10-20 1979-10-19 Therapy and pharmacologic medicine for occulusive respiratory tract disease and heart disease
US06/273,213 US4804664A (en) 1978-10-20 1981-06-12 Method and pharmaceutical preparation for treating chronic obstructive airway disease and cardiac disease, and intermediates for the preparation of therapeutically active xanthine derivatives
SG32486A SG32486G (en) 1978-10-20 1986-04-07 Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease
HK714/86A HK71486A (en) 1978-10-20 1986-09-25 Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7810946A SE7810946L (sv) 1978-10-20 1978-10-20 Metod att behandla kronisk obstruktiv luftvegssjukdom

Publications (1)

Publication Number Publication Date
SE7810946L true SE7810946L (sv) 1980-04-21

Family

ID=20336144

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7810946A SE7810946L (sv) 1978-10-20 1978-10-20 Metod att behandla kronisk obstruktiv luftvegssjukdom

Country Status (8)

Country Link
US (2) US4325956A (sv)
EP (2) EP0011609B2 (sv)
JP (1) JPS5557517A (sv)
AU (1) AU529805B2 (sv)
HK (1) HK71486A (sv)
IE (1) IE49623B1 (sv)
SE (1) SE7810946L (sv)
SG (1) SG32486G (sv)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7810947L (sv) * 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
SE8002910L (sv) * 1980-04-18 1981-10-19 Draco Ab 3,8-dialkylxantiner, forfarande for deras framstellning, beredning och metoder for behandling av kronisk obstruktiv luftvegssjukdom och kardiovaskulera sjukdomar
DE3127237A1 (de) * 1981-07-10 1983-01-20 Hoechst Ag, 6000 Frankfurt Magenvertraegliche arzneiformen von xanthinderivaten und verfahren zu ihrer herstellung
US4562194A (en) * 1984-07-31 1985-12-31 Warner-Lambert Company Synergistic non-steroidal anti-inflammatory compounds and compositions thereof
SE8602887D0 (sv) * 1986-06-27 1986-06-27 Draco Ab New chemical method
IT1229195B (it) * 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
EP0407651A3 (en) * 1989-07-10 1991-08-07 J. Uriach & Cia. S.A. Use of 1,3-diisobutyl-8-methylxanthine as a bronchodilator and antiallergy agent
US5270316A (en) 1989-10-20 1993-12-14 Kyowa Hakko Kogyo Co., Ltd. Condensed purine derivatives
JPH08507068A (ja) * 1993-02-26 1996-07-30 シェリング・コーポレーション ２−ベンジル−多環式グアニン誘導体およびそれらの製造方法
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
CN1178940C (zh) * 1999-08-31 2004-12-08 范德比尔特大学 A2b腺苷受体的选择性拮抗剂
US20020012946A1 (en) * 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
JP2005538190A (ja) * 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US7655636B2 (en) * 2004-10-20 2010-02-02 Gilead Palo Alto, Inc. Use of A2A adenosine receptor agonists
US7732595B2 (en) * 2006-02-03 2010-06-08 Gilead Palo Alto, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CA2662278C (en) * 2006-09-01 2011-11-22 Cv Therapeutics, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
JP2010515081A (ja) * 2007-01-03 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心筋灌流画像化
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
JP2016027279A (ja) * 2014-07-02 2016-02-18 日本精工株式会社 冠型保持器及びアンギュラ玉軸受

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
GB683523A (en) 1948-08-18 1952-12-03 Beecham Res Lab The manufacture of purine derivatives
JPS53890B2 (sv) * 1972-04-22 1978-01-12
GB1435916A (en) * 1972-05-11 1976-05-19 Beecham Group Ltd Pharmaceutical weight-reducing compositions
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
CA1077932A (en) * 1976-03-31 1980-05-20 Berlex Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases

Also Published As

Publication number Publication date
IE49623B1 (en) 1985-11-13
EP0045094A1 (en) 1982-02-03
EP0045094B1 (en) 1984-05-16
HK71486A (en) 1986-10-03
EP0011609A3 (en) 1980-07-23
AU5187279A (en) 1980-05-01
JPS5557517A (en) 1980-04-28
AU529805B2 (en) 1983-06-23
EP0011609B2 (en) 1988-05-11
US4325956A (en) 1982-04-20
IE791988L (en) 1980-04-20
EP0011609A2 (en) 1980-05-28
EP0011609B1 (en) 1983-04-13
SG32486G (en) 1989-12-22
JPS6340167B2 (sv) 1988-08-10
US4804664A (en) 1989-02-14

Similar Documents

Publication Publication Date Title
SE7810946L (sv) Metod att behandla kronisk obstruktiv luftvegssjukdom
FR2351645A1 (fr) Procede de fabrication d'un cercueil en carton-pate et cercueil ainsi obtenu
IT1164517B (it) Processo per formare un'apertura di strette dimensioni su un corpo di silicio
SE8002292L (sv) 4-amino-3-kinolinkarboxylsyror och estrar som antisekretoriska anti-ulcerosa foreningar
BG30474A3 (en) Method for obtaining of 6- propyl- 8- methoxymethyl- or- methylmercaptomethylergolin and simular compounds
BG33886A3 (en) Method for heterocyclic compounds producing
FI875666A (sv) Förfarande för framställning av en terapeutiskt aktiv kinolinförening
BG27905A3 (en) Method of obtaining of phospinous acids
ES508490A0 (es) "un metodo de produccion de derivados de tiazolidina".
IT1122800B (it) Procedimento per l'erezione di preriscaldatori d'aria
SE8102337L (sv) Radiomottagare
BE859479A (fr) Procede de fabrication d'orthoacetates d'alcoyle
FR2360583A1 (fr) B-azolylcetones utiles comme fongicides
ATE9347T1 (de) Salze von endo-8-methyl-8-syn-alkyl-8-
RO75404A (ro) Circuit pentru controlul saturatiei unui tranzistor
ATE84023T1 (de) 4 halogen-2-oxyimino-3-oxo-buttersaeure.
DE68905406D1 (de) Chinolin-verbindung.
SE7903336L (sv) N-alkenylmoranolin-derivat
NO792126L (no) Karbazolderivater.
SE7902724L (sv) Substituerade n-iminometylpiperidiner
DE69201972D1 (de) Verfahren zum Herstellen von Hemiketalen und Hemithioketalen.
BR8202475A (pt) Processo para a producao de um composto heterocilico de 5 membros
BG34759A3 (en) Method for stabilizing halogenating compounds
SU535987A1 (ru) Способ изготовлени тепловой трубы
IT7923176A0 (it) Dispositivo per l'applicazione di tratte di nastro su di un pezzo disposto piano.

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 7810946-9